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Since the initial description of the nm23 gene as an antimetastatic
factor whose expression is correlated inversely with tumour
metastatic potential in murine melanoma cell lines (Steeg et al,
1988), numerous studies have supported its suppressive effects on
tumour metastasis (Leone et al, 1993; Tokunaga et al, 1993; Iizuka
et al, 1995; Russell et al, 1998). Different conclusions have been
drawn from experiments with a variety of tumours (Higashiyama
et al, 1992; Lindmark et al, 1996; Shimada et al, 1998). Thus, the
relation of nm23-H1 to tumour metastasis is still controversial,
although this discrepancy may be due in part to differences in the
specificities of antibodies used. nm 23-H1 encodes nucleoside
diphosphate kinase A, which is responsible for the synthesis of
most non-ATP nucleoside triphosphates, suggesting that this
protein might be involved in a wide variety of biological
phenomena in the cell (Otero et al, 1999). Recently, the role of
nm23-H1 in sensitivity to anticancer agents has attracted a great
deal of attention (Freije et al, 1997). In addition to the ant-
imetastatic property, nm23-H1 has been shown to be associated
with sensitivity to cisplatin in breast carcinoma (Ferguson et al,
1996) and ovarian carcinoma (Scambia et al, 1996).
Our recent study of oesophageal squamous cell carcinoma
(OSCC) revealed that expression of nm23-H1 protein was
associated inversely with prognosis of patients with OSCC after
cisplatin-based chemotherapy (Iizuka et al, 1999a). Additionally,
our in vitro study in OSCC cell lines demonstrated that downregu-
lation of nm23-H1 protein by antisense transfection caused
increased resistance to cisplatin but not 5-fluorouracil or etopo-
side (Iizuka et al, 1999b). Ferguson et al (1996) demonstrated
increased formation of interstrand DNA cross-links of cisplatin in
breast cancer cells that express high levels of nm23-H1. However,
the mechanism remains unclear. We hypothesized the specific
roles of nm23-H1 in cisplatin-induced cytotoxity on the basis of
evidence that there was no association between nm23-H1 status
and sensitivity to 5-fluorouracil and etoposide. Because cisplatin-
induced cytotoxicity is mainly due to formation of adducts with
DNA (Mann et al, 1991), in the present study we used an antisense
transfectant of nm23-H1 derived from an OSCC cell line to inves-
tigate the association of nm23-H1 with both nuclear and mito-
chondrial DNA damage induced by cisplatin (Iizuka et al, 1999b)
and then evaluated the relation of nm23-H1 to apoptosis induced
by cisplatin. Additionally, we examined the relation of nm23-H1
expression to Na+, K+-ATPase activity, which contributes to
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Summary Previously, we showed that expression of nm23-H1 is associated inversely with sensitivity to cisplatin in human oesophageal
squamous cell carcinoma (OSCC). The present study was undertaken to investigate the association of nm23-H1 expression with cisplatin-
induced DNA damage in OSCC using antisense nm23-H1 transfectants. YES-2/AS-12, an antisense nm23-H1-transfected OSCC cell line,
showed significantly reduced expression of intracellular nm23-H1 protein compared with that in parental YES-2 cells and YES-2/Neo
transfectants. Surface expression of nm23-H1 protein was not observed in any of the three cell lines. PCR analysis for DNA damage
demonstrated that YES-2/AS-12 cells were more resistant to nuclear and mitochondrial DNA damage by cisplatin than were YES-2/Neo cells.
In addition, mitochondrial membrane potentials and DNA fragmentation assays confirmed that YES-2/AS-12 was more resistant than YES-
2/Neo to apoptosis induced by cisplatin. In contrast, YES-2/AS-12 was more sensitive to ouabain, a selective inhibitor of Na+, K+-ATPase,
than YES-2 and YES-2/Neo. Pre-treatment with ouabain resulted in no differences in cisplatin sensitivity between the three cell lines
examined. Intracellular platinum level in YES-2/AS-12 was significantly lower than that in YES-2 and YES-2/Neo following incubation with
cisplatin, whereas ouabain pre-treatment resulted in no differences in intracellular platinum accumulations between the three cell lines. Our
data support the conclusion that reduced expression of intracellular nm23-H1 in OSCC cells is associated with cisplatin resistance via the
prevention of both nuclear and mitochondrial DNA damage and suggest that it may be related to Na+, K+-ATPase activity, which is responsible
for intracellular cisplatin accumulation. © 2000 Cancer Research Campaign
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YES-2 is a human OSCC cell line established in our laboratory
(Oka et al, 1996a). YES-2/AS-12 is an antisense-transfected clone
that has a 23-fold reduction in the expression level of nm23-H1
protein, and that is approximately 4-fold more resistant to cisplatin
than the parental YES-2 cell line and the YES-2/Neo cell line
(Iizuka et al, 1999b). YES-2 was maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) (Nissui, Tokyo, Japan) supple-
mented with 5% foetal calf serum (FCS), 100 U ml–1 penicillin G,
and 100 µ g ml–1 streptomycin. Both YES-2/AS-12 and YES-
2/Neo were maintained in the above culture medium containing
200 µ g ml–1 of G418.
Assessment of intracellular and surface levels of 
nm23-H1 protein
For detection of intracellular nm23-H1, 5 × 105 cells were fixed
and then incubated with PBS containing 5% normal mouse serum
for 30 min to reduce nonspecific reactions. Subsequently, the cells
were treated with 200 µ l of permeabilizing solution (Becton
Dickinson, San Jose CA, USA) at 37° C for 10 min. After being
washed in PBS, they were reacted with 0.5 µ g of FITC-conjugated
H1-229 (Seikagaku, Tokyo, Japan) at 37° C for 60 min. Finally,
measurements of intracellular nm23-H1 levels were made with a
Facsort fluorescence-activated cell sorter (Becton Dickinson).
FITC-conjugated mouse IgG2a was used as an isotype-matched
control for anti-nm23-H1 antibody. Analysis of surface nm23-H1
was also performed using the above method without a permeabi-
lizing solution step.
PCR analysis of nuclear and mitochondrial DNA
damage induced by cisplatin
The cells were seeded into 60-mm tissue culture dishes at 37° C in
DMEM with 5% FCS. When the cells were subconfluent, the
medium was aspirated and replaced with serum-free medium.
Cells were then treated with 25–200 µ g ml–1 of cisplatin (Nippon
Kayaku, Tokyo, Japan). Following incubation for 2 h at 37° C,
cells were washed three times with cold PBS, pelleted by centrifu-
gation at 2000 rpm at 4° C and frozen for DNA isolation. Genomic
DNA was extracted by DNAzol (Gibco-BRL, Bethesda MD,
USA) and the concentration of DNA was determined using a
GeneQuant II spectrophotometer (Pharmacia Biotech, Tokyo,
Japan). Fifty nanograms of total genomic DNA was amplified by
PCR as described by Daoud et al (1995). Namely, a 1.1-kb 
fragment of mitochondrial DNA was amplified by 18 cycles 
of PCR with Mito A and Mito B primers (Mito A, 5′ -
GCGGTTGTTGATGGGTGAGT-3′ ; Mito B, 5′ -CCACAT-
CACTCGAGACGTAA-3′ ) (Yoon et al, 1991), and a 0.536-kb
fragment of nuclear β -globin gene was amplified by 30 cycles 
of PCR with the β -globin 1 and β -globin 2 primers (β -globin 1, 
5′ -GGTTGGCCAATCTACTCCCAGG-3′ ;  β -globin 2, 5′ -
GCTCACTCAGTGTGGC AAAG-3′ ) (Saiki et al, 1988). The
PCR products were separated by electrophoresis on a 1% agarose
gel and stained with ethidium bromide. Quantitative PCR analysis
was performed in 50 µ l PCR reactions containing 0.5 µ l (5 µ Ci) of
α [32P]-dCTP as described above. The PCR products were
subjected to 5% polyacrylamide gel electrophoresis and autoradi-
ography, and the associated radioactivity was measured with an
imaging analyser (BAS-2000) (Fuji Photo Film, Tokyo, Japan).
Analysis of mitochondrial membrane potential (MMP)
Loss of mitochondrial membrane potential (MMP) was analysed
by flow cytometry as previously described (Kim et al, 1997; Fulda
et al, 1999). Briefly, 5 × 105 cells were treated with 0, 2.5 µ g ml–1,
5 µ g ml–1, or 10 µ g ml–1 of cisplatin for 24 h. After cisplatin treat-
ment, cells were resuspended and incubated with 40 nM 3,3′ -
dihexyloxacarbocyanine iodide (DiOC6(3)) (Molecular Probes
Inc, Eugene OR, USA) for 15 min at 37° C. Finally, measurement
of MMP was done with a Facsort fluorescence-activated cell sorter
(Becton Dickinson) (see Figure 4A).
Analysis of DNA fragmentation
DNA fragmentation assay was performed as previously described
(Oka et al, 1996b). Briefly, YES-2/Neo and YES-2/AS-12
cells were incubated with 5 µ g ml–1 of cisplatin for 24 h. After
being washed with PBS, the cells were collected and treated
with proteinase K (100 µ g ml–1) and RNase (1 µ g ml–1). DNA was
extracted with DNAzol (Gibco-BRL), and then 3 µ g of DNA
was separated by electrophresis on 1.5% agarose gels. Finally, the
DNA was visualized by staining with ethidium bromide (see
Figure 4B).
Inhibitory effect of ouabain on proliferation
Cells were plated at 5 × 103 per 100 µ l in 96-well plates in DMEM
with 5% FCS, and allowed to attach overnight. Three wells were
treated with 10–1000 nM of ouabain (Nacalai Tesque, Tokyo,
Japan). After 24 h, 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H
tetrazolium bromide (MTT) assay was performed as previously
described (Hazama et al, 1999; Iizuka et al, 2000). Cell viability
was calculated as the percentage of control cultures that were not
exposed to ouabain.
Effects of ouabain on cisplatin-induced cytotoxicity
Cells were plated at 5 × 103 per 100 µ l in 96-well plates in DMEM
with 5% FCS, and allowed to attach overnight. Cells were
incubated in the same medium with or without 200 nM ouabain
(Nacalai Tesque) for 1 h. The medium was then aspirated and
replaced with DMEM containing 5% FCS and 5 µ g ml–1 of
cisplatin or DMEM with 5% FCS. After 48 h, MTT assay was
performed. Cell viability was calculated as the percentage of
control cultures that were not exposed to both ouabain and
cisplatin.
Cisplatin accumulation
Intracellular platinum (Pt) levels were analysed using a modifica-
tion of previously described procedure (Ohmori et al, 1994;
O’Neill et al, 1999). Briefly, 1 × 106 cells were incubated in the
same medium with or without 200 nM ouabain for 1 h at 37° C.
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to 15 µ g ml–1 of cisplatin for 2 h under the same conditions.
Subsequently, the cells were washed twice with ice-cold PBS, then
harvested in 500 µ l of PBS and gently sonicated on ice. Protein
content was determined using a Bio-Rad Protein Assay Kit (Bio-
Rad, Richmond CA, USA). The cell extracts were analysed for
platinum using atomic absorption flame emission spectropho-
tometer (AA-6700F; Shimazu, Tokyo, Japan). The results were
expressed as pmol Pt mg–1 protein.
Statistical analysis
The data were analysed by a one-way analysis of variance
(ANOVA), and where appropriate, Scheffe’s adjustment for
multiple comparisons was used. P < 0.05 was considered statisti-
cally significant.
RESULTS
Modulation of intracellular and surface nm23-H1
expression by antisense transfection
When compared to that of controls, the immunoreactivity of intra-
cellular nm23-H1 protein in YES-2, YES-2/Neo, and YES-2/AS-
12 cells were 66.1 ± 1.8%, 64.7 ± 1.5%, and 12.8 ± 2.1%,
respectively. Thus, YES-2/AS-12, an antisense nm23-H1-
transfected OSCC cell line, showed significantly reduced expres-
sion of intracellular nm23-H1 protein compared with parental
YES-2 and YES-2/Neo (P < 0.0001 for both, one-way ANOVA)
(Figure 1). These results were consistent with previous data
obtained by Western blot analysis (Iizuka et al, 1999b). On the
other hand, surface expression of nm23-H1 was not detected in the
cell lines examined (Figure 1).
Nuclear and mitochondrial DNA damage induced by
cisplatin
To evaluate differences in DNA damage caused by cisplatin
between YES-2/AS-12 and YES-2/Neo cells, PCR-based assay
was performed according to previously described methods (Daoud
et al, 1995). This assay is based on the observation that extreme
damage to the DNA templates can block the Taq polymerase.
Indeed, it was reported that treatment of cells with cisplatin
decreased amplification of a specific DNA fragment compared to
that of the same DNA fragment in untreated cells (Kalinowski 
et al, 1992).
In this study, we used primers that amplify a 0.536-kb fragment
of the β -globin gene (Saiki et al, 1988) and a 1.1-kb fragment of
the mitochondrial DNA (Yoon et al, 1991) to evaluate nuclear and
mitochondrial DNA damage induced by cisplatin, respectively.
Comparison of ethidium bromide staining showed a significant
reduction in amplification of the β -globin gene fragment in YES-
2/Neo cells at levels of cisplatin above 50 µ g ml–1 (Figure 2). On
the contrary, amplification of this same fragment of YES-2/AS-12
cells was not inhibited even when the cells were treated with 100
µ g ml–1 of cisplatin. Amplification of the mitochondrial DNA frag-
ment of YES-2/Neo cells was inhibited by 100 µ g ml–1 of cisplatin,
but amplification of this same fragment of YES-2/AS-12 cells was
not affected by 100 µ g ml–1 of cisplatin. Based on these findings,
we used 100 µ g ml–1 of cisplatin to evaluate quantitatively the
difference in DNA damage between YES-2/AS-12 and YES-
2/Neo cells. Quantitative PCR showed that after 2-h exposure of
YES-2/AS-12 cells to 100 µ g ml–1 of cisplatin, the level of intact
β -globin gene was 93.1% compared to that of untreated cells. This
percentage dropped to approximately 17.5% in cisplatin-treated
YES-2/Neo cells (Figure 3). Moreover, the level of intact mito-
chondrial DNA was 95.5% in cisplatin-treated YES-2/AS-12 cells
whereas it was 57.9% in cisplatin-treated YES-2/Neo cells. Thus,
both nuclear and mitochondrial DNAs of YES-2/AS-12 cells
showed increased resistance to cisplatin-induced damage when
compared to the results with YES-2/Neo cells. There were no
differences in nuclear or mitochondrial DNA damage caused by
cisplatin between parental YES-2 and YES-2/Neo cells (data not
shown).
Apoptosis induced by cisplatin in YES-2/Neo and 
YES-2/AS-12 cells
Flow cytometric analysis using DiOC6(3) showed that 10.7%,
10.7%, 13.4%, and 42.9% of mitochondrial membrane potential
(MMP) in YES-2/AS-12 cells was lost after 24-h exposure to 0,
2.5 µ g ml–1, 5 µ g ml–1, and 10 µ g ml–1 of cisplatin, respectively.
MMP loss in YES-2/Neo cells was 11.4%, 37.5%, 67.3%, and
86.8%, respectively. (Figure 4A). After 24-h exposure to 5 µ g ml–1
of cisplatin, DNA fragmentation was detected more strongly in
YES-2/Neo than in YES-2/AS-12 cells (Figure 4B).
nm23-H1 and DNA damage by cisplatin 1211
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Figure 1 Intracellular and surface levels of nm23-H1 protein in parental
YES-2 cells (A), YES-2/Neo cells (B), and YES-2/AS-12 cells (C). Left and
right panels show intracellular and surface expression of nm23-H1 protein,
respectively. Shaded histogram (left panel) and bold line (right panel),
reactivity with FITC-conjugated H1-229 specific for nm23-H1 protein; thin line
(left and right), reactivity with FITC-conjugated mouse IgG2aModulation of cisplatin resistance by ouabain
Our present data showed that downregulation of intracellular
nm23-H1 expression caused increased resistance to cisplatin-
induced DNA damage in OSCC cell lines. Therefore, we exam-
ined the relation of nm23-H1 status to the activity of Na+,
K+-ATPase, which affects cisplatin influx (Andrews et al, 1991).
As shown in Figure 5, after 24-h exposure to ouabain, a selective
inhibitor of Na+,K+-ATPase, the proliferation of each cell line was
inhibited in a dose-dependent manner. The YES-2/AS-12 cell 
line was more sensitive to ouabain than were the YES-2 and 
YES-2/Neo cell lines at doses of 100–1000 nM (P<0.001 for both,
one-way ANOVA). As shown in Table 1, after 48-h exposure to
cisplatin without ouabain pretreatment, cell viability of YES-
2/AS-12 was 47.9 ± 2.2% when compared to that of untreated
1212 N Iizuka et al
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Figure 2 PCR amplification of nuclear (n) and mitochondrial (mt) DNA
damaged by cisplatin in YES-2/Neo cells (left) and YES-2/AS-12 cells (right).
The fragment (536 bp) of the genomic β -globin gene and the fragment
(1.1 kb) of mitochondrial DNA were amplified by PCR to evaluate nuclear and
mitochondrial DNA damage after cisplatin treatment. PCR products were
separated electrophoretically on a 1% agarose gel and stained with ethidium
bromide. MW = molecular weight marker (1 Kb DNA Ladder, Gibco-BRL,
Rockville MD, USA)
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YES-2/Neo YES-2/AS-12 YES-2/AS-12 YES-2/Neo
n DNA damage mt DNA damage
Figure 3 Quantitative analysis for nuclear (n) and mitochondrial (mt) DNA
damage by cisplatin. (A) Autoradiograph showing PCR products of genomic
β -globin gene (upper panel) and mitochondrial DNA (lower panel) in YES-
2/Neo (left) and YES-2/AS-12 (right) cells. Total DNA was extracted from
YES-2/Neo and YES-2/AS-12 cells with or without 100 µ g ml–1 cisplatin
treatment. Subsequently, quantitative PCR analysis was performed as
described in ‘Materials and Methods’. The PCR products were subjected to
5% polyacrylamide gel electrophoresis and autoradiography, and the
associated radioactivity was measured with an imaging analyser (BAS-2000)
(Fuji Photo Film, Tokyo, Japan). (B) Relative radioactivity is compared to that
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Figure 4 Apoptosis induced by cisplatin in YES-2/Neo and YES-2/AS-12 cells. (A) Loss of mitochondrial membrane potential (MMP) in YES-2/Neo (left) and
YES-2/AS-12 (right) cells. Cells were treated with 0, 2.5, 5 or 10 µ g ml–1 of cisplatin for 24 h. They were resuspended and incubated with 40 nM DiOC6(3) for 
15 min at 37° C. Finally, loss of MMP was measured with a Facsort fluorescence-activated cell sorter (Becton Dickinson). (B) DNA fragmentation induced by 
5 µ g ml–1 of cisplatin for 24 h. MW = molecular weight marker (1 Kb DNA Ladder, Gibco-BRL).cells. Cell viabilities of YES-2 and YES-2/Neo were 14.8 ± 3.1%
and 16.1 ± 2.4%, respectively. Thus, YES-2/AS-12 showed signif-
icantly increased resistance to cisplatin as compared to YES-2 and
YES-2/Neo (P = 0.0009 and P = 0.0006, respectively, one-way
ANOVA). This result was consistent with our previous data
(Iizuka et al, 1999b). In contrast, after 48-h exposure to cisplatin
with ouabain pre-treatment, cell viabilities of YES-2, YES-2/Neo,
and YES-2/AS-12 were 54.1 ± 1.7%, 54.3 ± 1.6%, and 57.4 ±
2.4%, respectively. Thus, there was no significant difference in
cisplatin sensitivity between the three cell lines when they were
pretreated with 200 nM ouabain (Table 1). After 2-h exposure to
15 µ g ml–1 of cisplatin, the amount of platinum accumulated in
YES-2, YES-2/Neo, and YES-2/AS-12 were 184.5± 24.8, 189.6±
21.0, and 95.0 ± 13.3 pmol mg–1 protein, respectively. Thus, intra-
cellular platinum level in YES-2/AS-12 was significantly lower
than that in YES-2 and YES-2/Neo (P = 0.029 and P = 0.019,
respectively), whereas ouabain pre-treatment resulted in no differ-
ences in intracellular platinum levels between the three cell lines
(Table 2).
DISCUSSION
Cisplatin is a widely used anticancer agent that acts by forming
adducts with DNA and initiating the response to cellular injury
(Andrews et al, 1991; Mann et al, 1991). For treatment of
oesophageal squamous cell carcinoma (OSCC), however,
cisplatin-based chemotherapy has not led to significant improve-
ment in overall survival of OSCC patients (Kok et al, 1996; Bosset
et al, 1997). Therefore, it is necessary to elucidate the mechanism
of cisplatin resistance or sensitivity of OSCC. In addition to
numerous factors responsible for cisplatin resistance, our recent
study using the MTT assay revealed that downregulation of nm23-
H1 protein increases the resistance of OSCC cell lines to cisplatin
but not to 5-fluorouracil or etoposide (Iizuka et al, 1999b). Our
present data demonstrate that downregulation of intracellular
nm23-H1 increases cellular resistance to cisplatin-induced DNA
damage in OSCC cells. Ferguson et al (1996) proposed that over-
expression of nm23-H1 increases formation of interstrand DNA
cross-links of cisplatin in human breast cancer cells. Therefore, it
is possible that the increased resistance to cisplatin-induced DNA
damage in YES-2/AS-12 cells is due in part to altered formation of
interstrand DNA cross-links of cisplatin. Our data also demon-
strate that downregulation of intracellular nm23-H1 increases
resistance to cisplatin-induced mitochondrial DNA damage in
OSCC cells. The relation of nm23-H1 to mitochondrial DNA
damage indicates the significance of nm23-H1 in cisplatin-induced
cytotoxicity, because mitochondrial injury has been shown to be a
central event in the early stages of cell death (Olivero et al, 1995)
and it has been shown that there is decreased removal of cisplatin-
DNA adducts in damaged mitochondrial DNA compared to
damaged nuclear DNA (Olivero et al, 1997). In addition, alter-
ations in mitochondrial functions, such as permeability transitions,
play a central role in the apoptotic process (Kroemer et al, 1998;
Eguchi et al, 1999). We demonstrate that downregulation of intra-
cellular nm23-H1 decreases cisplatin-induced loss of mitochon-
drial membrane potential and DNA fragmentation. This result
might be due to the difference in mitochondrial DNA damage in
the OSCC cell lines.
We confirmed that downregulation of nm23-H1 did not alter 
the expression of GST-π and metalothionein mRNAs (data not
shown). Since these genes or proteins have been reported to be
associated with cellular detoxification in cisplatin-induced cyto-
toxicity and have been demonstrated to be elevated in cisplatin
resistance cell lines (Timmer-Bosscha et al, 1993; Hishikawa 
et al, 1997), this result suggested the contribution of nm23-H1 
to another mechanism in cisplatin resistance other than cellular
detoxification. Cisplatin uptake is also thought to be associated
with the activity of Na+ K+-ATPase (Andrews et al, 1991; Mann et
al, 1991; Blok et al, 1999). Increased sensitivity to ouabain, a
selective inhibitor of Na+,K+-ATPase, is observed in cisplatin-
resistant cancer cells (Ohmori et al, 1994), suggesting that lower
Na+, K+-ATPase activity is essential for cisplatin resistance. On the
contrary, cisplatin-resistant cancer cells were reported to be cross-
resistant to ouabain (Andrews et al, 1991). This discrepancy might
be due in part to difference in the cancer cell type used. Consistent
nm23-H1 and DNA damage by cisplatin 1213










Figure 5 Inhibitory effects of ouabain on proliferation of OSCC cell
lines. Cells were treated with 10–1000 nM of ouabain. After 24 h,
MTT assay was performed as described in ‘Materials and Methods’. Cell
viability was calculated as the percentage of control cultures which were not
exposed to ouabain. Data are mean values ± SE of three individual
experiments (*P < 0.001 vs YES-2 or YES-2/Neo)
Table 1 Modulation of cisplatin sensitivity by ouabain pre-treatment in
oesophageal cancer cells
Cell viability (%)
Ouabain ( + ) Ouabain ( )
Treatment Cisplatin ( ) Cisplatin (+) Cisplatin (+)
YES-2 91.9 ± 2.0* 54.1 ± 1.7** 14.8 ± 3.1***
YES-2/Neo 91.4 ± 3.2* 54.3 ± 1.6** 16.1 ± 2.4***
YES-2/AS-12 86.7 ± 2.3* 57.4 ± 2.4** 47.9 ± 2.2***
Data are mean values ± SE of three individual experiments.
*, **Not significant. ***P = 0.0009 (YES-2/AS-12 versus YES-2); 
***P = 0.0006 (YES-2/AS-12 versus YES-2/Neo).
Table 2 Cellular accumulation of cisplatin and inhibitory effect of ouabain
Cisplatin accumulation
(pmol mg 1 protein)
Pre-treatment of
Ouabain ( ) (+)
YES-2 184.5 ± 24.8* 99.5 ± 7.3**
YES-2/Neo 189.6 ± 21.0* 105.1 ± 10.2**
YES-2/AS-12 95.0 ± 13.3* 80.4 ± 9.5**
Data are mean values ± SE of four individual experiments.
*P=0.029 (YES-2/As-12 versus YES-2); *P = 0.019 (YES-2/AS-12 versus
YES-2/Neo). **Not significant.with the results by Ohmori et al (1994), our results showed that
YES-2/AS-12 cells were more sensitive to ouabain than were YES-
2 and YES-2/Neo cells. Intracellular platinum level in YES-2/AS-
12 was significantly lower than that in YES-2 and YES-2/Neo
following incubation with cisplatin. The amount of platinum accu-
mulated in YES-2/AS-12 was about 50% of that in YES-2 or YES-
2/Neo. This result is also supported by the report that
approximately half of the cisplatin accumulation in the cell is due to
Na+,K+-ATPase (Ohmori et al, 1994). Additionally, inhibition of
Na+,K+-ATPase by ouabain pre-treatment resulted in no differences
in intracellular platinum accumulations between the three cell lines.
These findings support the possibility that activity of Na+,K+-
ATPase is lower in YES-2/AS-12 cells than in YES-2 and YES-
2/Neo cells. Taken together, close relation of intracellular nm23-H1
to Na+,K+-ATPase activity may confer cisplatin resistance by
modulating intracellular accumulation of cisplatin. The relation
between nm23-H1 expression and Na+, K+-ATPase activity is not
well understood. Nm23/nucleoside diphosphate kinases are ubiqui-
tous enzymes which produce nucleoside triphosphates other than
ATP. Under physiological conditions, the reaction occurs at the
expense of ATP as a phosphate donor (Ishikawa et al, 1992). Thus,
the possible interaction between the two enzymes may be explained
in part by the fact that nm23/nucleoside diphosphate kinase and
Na+,K+-ATPase function as ATP-scavenging enzymes. It was also
shown that Na+ and K+ regulate phosphorylation of nm23 in human
airway epithelium (Marshall et al, 1999). Thus, the two enzymes
might be associated closely by intracellular cation levels. Further
studies are necessary to elucidate possible interaction between
these two enzymes at the mRNA and protein levels.
Urano et al (1993) demonstrated the presence of nm23-H1 on
the surface of some cancer cells, indicating a possible extracellular
role of this protein. In addition, Zaborina et al (1999) showed
secretion of nucleoside diphosphate kinase from macrophages
stimulated by Mycobacterium bovis BCG. In the present study,
however, expression of nm23-H1 was not observed on the surface
of the three OSCC examined. Additionally, nm23-H1 was not
detected on the surfaces of the other five OSCC cell lines (data not
shown). Thus, with respect to OSCC, surface nm23-H1 does not
exist or function biologically.
Finally, our data support the conclusion that reduced expression
of intracellular nm23-H1 in OSCC cells is associated with cisplatin
resistance via the prevention of both nuclear and mitochondrial
DNA damage. This is due in part to decreased activity of Na+,K+-
ATPase, which is responsible for intracellular cisplatin accumula-
tion. These findings suggest the participation of nm23-H1 in
antitumour activity of cisplatin as a new biological role of this
protein in addition to the antimetastatic property. Thus, modulation
of intracellular nm23-H1 in tumour cells may be a novel strategy to
maximize the effect of cisplatin-based chemotherapy for OSCC.
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